


## AMENDED CLAIMS

[received by the International Bureau on 31 August 2005 (31.08.2005);  
Original claims 1-75 are replaced by Amended Claims 1-75]




wherein:

R<sub>7</sub> is aryl optionally substituted with one or more groups selected from -OH, -NH<sub>2</sub>, -SH, halogen, a heterocyclic ring and hydrocarbyl; and

R<sub>8</sub> and R<sub>9</sub> are the same or different and are each hydrocarbyl, optionally substituted with one or more halogens or lower alkyl groups, or


R<sub>8</sub> and R<sub>9</sub> together form a heterocyclic ring having five, six or seven atoms, including the intervening nitrogen and optionally containing other heteroatoms, and also optionally substituted with one or more halogens or lower alkyl groups;



wherein:

K is as defined above; and

R<sub>10</sub> and R<sub>11</sub> are the same or different and each is an aryl group, optionally substituted with a second aryl group that may be the same or different and the aryl groups may be substituted with one or more groups selected from -OH, -NH<sub>2</sub>, -SH, halogen, a heterocyclic ring and hydrocarbyl;



wherein:


p is an integer from 1-3;

M<sub>1</sub>, M<sub>2</sub>, and M<sub>3</sub> are the same or different and each is S or O;

Z is S, C or P;

R is hydrocarbyl or OR<sub>35</sub>, where R<sub>35</sub> is H or hydrocarbyl; and

R<sub>12</sub> and R<sub>13</sub> are the same or different and each is hydrocarbyl, a heterocyclic ring or lower alkyl, or R<sub>12</sub> and R<sub>13</sub> together form a ring;




wherein:

K is as defined above;

r is an integer from 1-3;

R<sub>14</sub> and R<sub>15</sub> are the same or different and each is aryl optionally substituted with one or more groups selected from -OH, -NH<sub>2</sub>, -SH, halogen, a heterocyclic ring and hydrocarbyl; and

5 R<sub>16</sub> and R<sub>17</sub> are the same or different and each is hydrocarbyl or a heterocyclic ring;




Formula VIII

wherein:

s is an integer from 1-10;

R<sub>20</sub>, R<sub>21</sub>, R<sub>22</sub> and R<sub>23</sub> are the same or different and each is H, aryl, optionally substituted with one or more halogen or lower alkyl groups, hydrocarbyl and a heterocyclic ring; and

10 R<sub>18</sub>, R<sub>19</sub> are the same or different and each is aryl optionally substituted with one or more groups selected from -OH, -NH<sub>2</sub>, -SH, halogen and lower alkyl;




Formula XII

wherein:

t is an integer from 1-5;

u is an integer from 1-2; and

15 R<sub>24</sub> is selected from H, a heterocyclic ring and hydrocarbyl, optionally substituted by halogen; and




Formula XIII

wherein:


Q is selected from CH<sub>2</sub>, NH, S and O; and

Z<sub>1</sub> and Z<sub>3</sub> are the same or different and selected from CH<sub>3</sub>, NH<sub>2</sub>, OH and SH.  
20 or tautomers thereof.


2. The complex of claim 1, wherein the compound is selected from



formula XI',



formula XII', and



formula XIII',


5 or a pharmaceutically acceptable salt thereof.

3. The complex of claim 1, which is in an animal.

4. The complex of claim 1, which is *in vitro*.

10

5. A complex comprising a compound of one of




Formula XIV


wherein:

$v$  is an integer from 1-3; and

$G_1$  and  $G_2$  are the same or different and each is selected from  $CH_2$ ,  $NH$ ,  $S$  and  $O$ ;




or the corresponding quinone



15 Formula XVI

wherein:

$R_{25}$ ,  $R_{26}$ ,  $R_{27}$ , and  $R_{28}$  are the same or different and each is selected from halogen and hydrocarbyl, particularly lower alkyl; and



Formula XVII


wherein:

K is as defined above, and



R<sub>29</sub> and R<sub>30</sub> are the same or different and each is aryl optionally substituted with one or more groups selected from -OH, -NH<sub>2</sub>, -SH, halogen and hydrocarbyl;

5 in association with a gastric releasing peptide (GRP).

6. The complex of claim 5, wherein the compound is of one of



OR



Formula XIV',

Formula XVI', or

Formula XVII'.

10 7. The complex of claim 5, which is in an animal (e.g., a mammal).

8. The complex of claim 5, which is *in vitro*.

15 9. A pharmaceutical composition comprising a compound of one of formula I - VIII, XII, or XIII as defined in claim 1, or one of formula XIV, XVI or XVII as defined in claim 5, and a pharmaceutically acceptable carrier.

20 10. The pharmaceutical composition of claim 9, wherein the compound is of one of formula I' - XIII' as defined in claim 2, or one of formula XIV', XVI', or XVII' as defined in claim 6.

11. A method for inhibiting an activity of an AM peptide, comprising contacting the peptide with an effective amount of a compound of one of formula I - VII as defined in claim 1.

25 12. The method of claim 11, wherein the compound is of one of formula I' - VII', as defined in claim 2.

said compound(s) and a pharmaceutically acceptable carrier, and, optionally, a container or packaging material.

54. The kit of claim 53, wherein the compound(s) is selected from formula I' through XIII', as defined in claim 2.

55. A kit suitable for treating a subject suffering from a condition mediated by an aberrant expression and/or activity of gastrin releasing peptide (GRP), comprising one or more of the compounds of formula XIV, XVI or XVII, as defined in claim 5, or a pharmaceutical composition comprising said compound(s) and a pharmaceutically acceptable carrier, and, optionally, a container or packaging material.

56. The kit of claim 55, wherein the compound(s) is of one of formula XIV', XVI' and/or XVII', as defined in claim 6.

57. A kit suitable for detecting an AM peptide, comprising

- a) one or more compounds selected from formula I - VIII, XII or XIII, as defined in claim 1, which is detectably labeled, and, optionally,
- b) means to detect the labeled compound associated with (bound to) the peptide.

58. The kit of claim 57, wherein the compound(s) is of one of formula I' - XIII', as defined in claim 2.

59. A kit suitable for detecting a GRP peptide, comprising

- a) one or more compounds selected from formula XIV, XVI, XVII, as defined in claim 5 and XV, as defined in claim 49, which is detectably labeled, and, optionally,
- b) means to detect the labeled compound associated with (bound to) the peptide.

60. The kit of claim 59, wherein the compound(s) is selected from formula XIV', XVI', XVII', as defined in claim 6 and XV', as defined in claim 50.

61. A kit of claim 53 or 55, wherein said compound is in a pharmaceutically acceptable carrier.

62. A method for inhibiting GRP-mediated angiogenesis in a subject in need of such treatment, comprising administering to the subject an effective amount of an agent that inhibits GRP, provided that the GRP-mediated angiogenesis is not angiogenesis involved in tumor growth or metastasis.

5

63. A method for preventing or treating condition mediated by GRP-mediated angiogenesis in a subject in need of such treatment, comprising administering to the subject an effective amount of an agent that inhibits GRP, provided that the condition is not angiogenesis dependent tumor growth.

10

64. A method for preventing or treating one of the following angiogenesis-mediated conditions in a subject:

arthritis (e.g, rheumatoid arthritis),

psoriasis,

15

benign growths caused by rapidly dividing cells,

brain ischaemia,

vascular diseases,

ocular diseases involving ocular neovascularization or related ocular diseases and disorders,

20

fibrosis,

deep venous thrombosis,

endometriosis, or

wrinkles,

comprising administering to the subject an effective amount of an agent that inhibits

25

GRP.

65. A method for inhibiting angiogenesis-mediated tumor growth in a subject in need of such treatment, comprising

administering to the subject an effective amount of an agent that inhibits GRP, and

30

detecting or monitoring the reduction in blood vessels (inhibition of angiogenesis).

66. The method of claim 62, wherein the agent is a compound of formula XV as defined in claim 49.

67. The method of claim 63, wherein the agent is a compound of formula XV as defined in claim 49.

5 68. The method of claim 64, wherein the agent is a compound of formula XV as defined in claim 49.

69. The method of claim 65, wherein the agent is a compound of formula XV as defined in claim 49.

10 70. The method of claim 62, wherein the agent is a compound of formula XV' as defined in claim 50.

71. The method of claim 63, wherein the agent is a compound of formula XV' as defined in claim 50.

15 72. The method of claim 64, wherein the agent is a compound of formula XV' as defined in claim 50.

20 73. The method of claim 65, wherein the agent is a compound of formula XV' as defined in claim 50.

74. A method for treating low blood pressure or an eating disorder in a subject in need of such treatment, comprising administering to the subject an effective amount of a compound of formula XV as defined in claim 49.

75. The method of claim 74, wherein the compound is of formula XV' as defined in claim 50.

**Statement Under Article 19(1)**

The claims have been amended in response to comments in the Written Opinion mailed 1 July 2005 in the above-referenced application. The following pages show the specific amendments made to the various claims.

**Explanation of Amendments**

In claim 1, formula VII has been amended to correct an obvious error. A correction to this formula under Rule 91 is being submitted concurrently with this amendment. Also, the definition of the variables R18 and R19 of formula VIII is clarified by the substitution of "and" for "or."

In claim 5, the variable  $G_3$  in the definition of formula XIV is replaced by  $G_2$ .

Claims 6, 7 and 8 now depend from claim 5.

Claim 9 refers to claim 1 with regard to formulas I-VIII, XII and XIII, and to claim 5 with regard to formulas XIV, XVI and XVII.

Claim 10 refers to claim 2 with regard to formulas I-XIII, and to claim 6 with regard to formulas XIV', XVI' and XVII'.

Claim 60 now depends from claim 59.

Claim 61 no longer recites a preamble.

Claim 64 no longer recites "(e.g., noncancerous melanomas)"

Applicant submits that the amended claims address certain points raised by the Examiner in the Written Opinion.